Günter U Höglinger
Höglinger, Günter 1971-
Höglinger, Günter U
Höglinger, Günter U. (Günter Ulrich), 1971-
VIAF ID: 47590159 (Personal)
Permalink: http://viaf.org/viaf/47590159
Preferred Forms
- 100 0 _ ‡a Günter U Höglinger
- 100 1 _ ‡a Höglinger, Günter U. ‡q (Günter Ulrich), ‡d 1971-
- 100 1 _ ‡a Höglinger, Günter ‡d 1971-
-
- 100 1 _ ‡a Höglinger, Günter ‡d 1971-
4xx's: Alternate Name Forms (12)
Works
Title | Sources |
---|---|
[18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy. | |
Analyse der protektiven Eigenschaften von a-Synuclein-spezifischen Antikörpern in einem neuartigen neuronalen Zellmodell für a-Synucleinopathien | |
Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. | |
Classification of atypical parkinsonism per pathology versus phenotype | |
Comprehensive miRNome-Wide Profiling in a Neuronal Cell Model of Synucleinopathy Implies Involvement of Cell Cycle Genes | |
[Current therapy studies in atypical Parkinson syndromes] | |
[Dementia with Lewy bodies] | |
The Differential Diagnosis and Treatment of Atypical Parkinsonism | |
l-DOPA-induced dyskinesia is associated with a deficient numerical downregulation of striatal tyrosine hydroxylase mRNA-expressing neurons. | |
Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. | |
Early Neurodegeneration in the Brain of a Child Without Functional PKR-like Endoplasmic Reticulum Kinase. | |
Entwicklung und Validierung von zwei Fragebögen als Screening-Tools zur Früherkennung der Progressiven Supranukleären Blickparese (PSP) | |
Exosomal secretion of α-synuclein as protective mechanism after upstream blockage of macroautophagy. | |
Extracellular vesicle-mediated transfer of genetic information between the hematopoietic system and the brain in response to inflammation | |
The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias. | |
Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy | |
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) | |
Hirntod und Organtransplantation | |
How Stimulus-responsive Extracellular Vesicle Release is Regulated and Associated to Lewy Body Disease | |
Investigating the interplay between α-Synuclein and fragile X mental retardation protein in Parkinson’s disease | |
Investigating the MAPT haplotype as a risk factor for neurodegenerative diseases with induced pluripotent stem cells | |
Investigation of the protective efficacy of α-synuclein-specific antibodies in a novel neuronal cell model for α-synucleinopathies | |
K-variant BCHE and pesticide exposure: Gene-environment interactions in a case-control study of Parkinson's disease in Egypt | |
Longitudinal TSPO expression in tau transgenic P301S mice predicts increased tau accumulation and deteriorated spatial learning | |
LRP1: A Novel Mediator of Tau Uptake | |
microRNA profiling: increased expression of miR-147a and miR-518e in progressive supranuclear palsy (PSP). | |
Mitochondrial complex 1 inhibition increases 4-repeat isoform tau by SRSF2 upregulation. | |
Mitochondrial damage by α-synuclein causes cell death in human dopaminergic neurons | |
Modifizierung der Progressive Supranuclear Palsy Rating Scale | |
Multiple molecular pathways stimulating macroautophagy protect from alpha-synuclein-induced toxicity in human neurons | |
Neurogenesis in substantia nigra of parkinsonian brains? | |
Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System | |
Neuronal precursor cells with dopaminergic commitment in the rostral migratory stream of the mouse | |
Neurotoxicity of Dietary Supplements from Annonaceae Species. | |
New insights into the relationship of neurogenesis and affect: tickling induces hippocampal cell proliferation in rats emitting appetitive 50-kHz ultrasonic vocalizations. | |
Outcomes of SARS-CoV-2 infections in patients with neurodegenerative diseases in the LEOSS Cohort | |
Parkinson-Syndrome kompakt, 2019: | |
Parkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus. | |
Pearls & Oy-sters: Ocular motor apraxia as essential differential diagnosis to supranuclear gaze palsy: Eyes up | |
PERK activation mitigates tau pathology in vitro and in vivo | |
PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes | |
[Pharmacotherapy of Parkinson's disease : Aspects of drug safety]. | |
Possible involvement of complement factor C1q in the clearance of extracellular neuromelanin from the substantia nigra in Parkinson disease | |
Preclinical Analysis of Fetal Human Mesencephalic Neural Progenitor Cell Lines: Characterization and Safety In Vitro and In Vivo | |
The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach | |
Quantitative evaluation of the human subventricular zone. | |
Rare Variants in Specific Lysosomal Genes Are Associated with Parkinson's Disease | |
Regulierung der Stimulations-sensitiven extrazellulären Vesikelfreisetzung und deren Assoziation mit der Lewy-Körperchen-Pathologie. | |
Rekrutierung peripherer Immunzellen in einem toxischen Multiple Sklerose Tiermodell | |
Reply to: "Brief Clinical Rating Scales Should Not Be Overlooked" | |
Reply to: MRI measures of brainstem in parkinsonian syndromes: Where we stand and where we need to go. | |
Rostro-caudal gradual loss of cellular diversity within the periventricular regions of the ventricular system. | |
Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial | |
en scientific article | |
Subcellular expression and neuroprotective effects of SK channels in human dopaminergic neurons | |
Symptomatic therapy of multiple system atrophy. | |
Tabibi Sabbu | |
Tau Diagnostics and Clinical Studies. | |
Tau links developmental to neurodegenerative diseases | |
Tauopathien | |
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. | |
Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. | |
Towards a consensus on developmental regression | |
Trifluoperazine rescues human dopaminergic cells from wild-type α-synuclein-induced toxicity. | |
Unbiased Screens for Modifiers of Alpha-Synuclein Toxicity | |
Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease | |
Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies | |
Validierung und Optimierung der Movement Disorders Society Diagnosekriterien für die Progressive Supranukleäre Blickparese | |
β-adrenoreceptors and the risk of Parkinson's disease |